Clinical Trial Update: Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance

View source ↗

Summary

A clinical trial update describes a study of durvalumab with or without olaparib in endometrial cancer patients under post-marketing surveillance; the trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Cancer | Status: RECRUITING